GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » COGS-to-Revenue

Santhera Pharmaceuticals Holding AG (XSWX:SANN) COGS-to-Revenue : 0.49 (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG COGS-to-Revenue?

Santhera Pharmaceuticals Holding AG's Cost of Goods Sold for the six months ended in Jun. 2023 was CHF1.93 Mil. Its Revenue for the six months ended in Jun. 2023 was CHF3.94 Mil.

Santhera Pharmaceuticals Holding AG's COGS to Revenue for the six months ended in Jun. 2023 was 0.49.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Santhera Pharmaceuticals Holding AG's Gross Margin % for the six months ended in Jun. 2023 was 51.05%.

Santhera Pharmaceuticals Holding AG COGS-to-Revenue Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG COGS-to-Revenue Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.07 0.70 - 0.48

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 - 0.30 1.40 0.49

Santhera Pharmaceuticals Holding AG COGS-to-Revenue Calculation

Santhera Pharmaceuticals Holding AG's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3.592 / 7.473
=0.48

Santhera Pharmaceuticals Holding AG's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.928 / 3.939
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG  (XSWX:SANN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Santhera Pharmaceuticals Holding AG's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1.928 / 3.939
=51.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Santhera Pharmaceuticals Holding AG COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » COGS-to-Revenue
Comparable Companies
XSWX:MOLN XSWX:NWRN XSWX:RLF XSWX:ADXN XSWX:EVE XSWX:KNRS XSWX:SPEX XSWX:XLS XSWX:BSLN XSWX:IDIA OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
SPHDF:USA SANNz:UK
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Website
https://www.santhera.com
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Headlines

No Headlines